Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) has issued an announcement.
Aurobindo Pharma has clarified to the National Stock Exchange of India and BSE that the recent significant increase in trading volumes of its shares is market driven and not the result of any undisclosed, company-specific information. The company noted that the Government of India’s newly notified Minimum Import Price on Penicillin-G, 6-APA and Amoxicillin Trihydrate—products manufactured by its wholly owned subsidiary Lyfius Pharma—has already been publicly detailed via an official DGFT notification and related media coverage, and therefore does not trigger any additional disclosure obligations. Aurobindo reiterated that it has no pending announcements or undisclosed events that could affect its share price or volumes and emphasized its ongoing compliance with SEBI’s disclosure regulations, aiming to reassure investors and regulators about the transparency of its communication and the integrity of its regulatory practices.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Through its subsidiaries, including Lyfius Pharma Private Limited, it produces key antibiotic inputs such as Penicillin-G and downstream derivatives, serving both domestic and international markets.
Average Trading Volume: 28,721
Technical Sentiment Signal: Hold
Current Market Cap: 662.2B INR
For detailed information about AUROPHARMA stock, go to TipRanks’ Stock Analysis page.